Multiple sclerosis is more prevalent in northern New Zealand than previously reported

Internal Medicine Journal

Volumn 33, Issue 3, 2003, Pages 79-83

  Chancellor, A M ^a   Addidle, M ^a   Dawson, K ^a  

^a TAURANGA HOSPITAL   (New Zealand)

Author keywords

interferon; Multiple sclerosis; Prevalence

Indexed keywords

BETA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HUMAN; ISLAND (GEOLOGICAL); MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; NEW ZEALAND; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; DISABLED PERSONS; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 0037344991     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00332.x     Document Type: Article

References (17)

1. Miller EH, Hammond SR, McLeod JG, Purdy G, Skegg DCG. Multiple sclerosis in Australia and New Zealand: Are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry 1990; 53: 903-5.
2. Skegg DCG, Corwin PA, Craven RS, Malloch JA, Pollock M. Occurrence of multiple sclerosis in the North and South of New Zealand. J Neurol Neurosurg Psychiatry 1987; 50: 134-9.
3. Miller DH, Hornerbrook RW, Dagger J, Fong R. Ethnic and HLA patterns related to multiple sclerosis in Wellington, NZ. J Neurol Neurosurg Psychiatry 1986; 49: 43-6.
4. Hornabrook RW. The prevalence of multiple sclerosis in New Zealand. Acta Neurol Scand 1971; 47: 426-38.
5. Miller DH, Hornerbrook RW, Purdy G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry 1992; 55: 341-6.
6. Cunningham JAK. The prevalence of disseminating sclerosis in Christchurch. NZ Med J 1972; 76: 417-8.
7. Compston A. Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62: 553-61.
8. Chadwick D. MS: disease modifying treatments and risk sharing. The Newsletter of the Association of British Neurologists 2002; 2: i-iv.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis; an expanded disability status scale (EDSS). Neurology 1983; 33: 1445-52.
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD et al. Recommended diagnostic criteria for Multiple Sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-7.
11. Poser CM, Patey DW, Scheinberg DH, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983; 13: 227-31.
12. Schoenberg BS. Calculating confidence intervals for rates and ratios. Neuroepidemiology 1983; 2: 257-65.
13. Bamford JN, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989; 20: 828.
14. Allison RS, Miller JHD. Prevalence and familial incidence of disseminated sclerosis. Ulster Med J 1954; 23: 5-23.
15. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
16. Simmons RD, Hall CA, Gleeson P, Everard G, Casse RF, O'Brien ED. Prevalence of multiple sclerosis in the Australian Capital Territory. Intern Med J 2001; 31: 161-7.
17. Chadwick D, Compston A, Miller D. Guidelines for the Use of Beta Interferons and Glatiramer Acetate in Multiple Sclerosis. London: The Association of British Neurologists; 2001. Available from: URL: http://www.theabn.org/downloads/msdoc.pdf